Antunes, Miguel M.Alves, MarianaFerreira, Joaquim JPinto, Fausto J.Caldeira, Daniel2020-10-232020-10-232020Cardiovasc Drugs Ther (2020).0920-3206http://hdl.handle.net/10451/44647© 2020 Springer Nature Switzerland AG. Part of Springer Nature.The use of aspirin, while well established in the secondary prevention of cardiovascular events, remains controversial in the primary prevention of these events in the general adult population. In this setting, aspirin showed a significant but modest decrease of cardiovascular event incidence at the cost of a significantly increased risk of bleeding, a pattern that is also seen in higher risk patients, such as diabetics. It becomes exceedingly important to identify other patient clusters that would benefit from cardiovascular risk reduction at the best benefit/risk ratio.engjournal article10.1007/s10557-020-07093-81573-7241